Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Sanofi-Aventis |
---|---|
Information provided by: | Sanofi-Aventis |
ClinicalTrials.gov Identifier: | NCT00447551 |
Primary objective To evaluate the degree of correction achievable with Sculptra for nasolabial folds, mid- and lower facial volume loss, jawline laxity and other signs of facial ageing.
To document the types and incidence of device-related adverse events with Sculptra.
Condition | Intervention | Phase |
---|---|---|
Skin Aging |
Drug: Poly-L-Lactic Acid |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Historical Control, Single Group Assignment, Safety/Efficacy Study |
Official Title: | Canadian Study of the Use of Injectable POLY-L-LACTIC Acid (Sculptra Therapy) in Aesthetic Medicine |
Enrollment: | 75 |
Study Start Date: | January 2007 |
Primary Completion Date: | April 2008 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
single group: Experimental |
Drug: Poly-L-Lactic Acid
Deep dermal injection
|
Ages Eligible for Study: | 18 Years to 75 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Responsible Party: | sanofi-aventis ( Medical Affairs Study Director ) |
Study ID Numbers: | POLYL_L_01777 |
Study First Received: | March 13, 2007 |
Last Updated: | August 20, 2008 |
ClinicalTrials.gov Identifier: | NCT00447551 |
Health Authority: | Canada: Health Canada |
Aesthetic facial volume enhancement |
Facies |